Hughes, G;
Bern, H;
Chiang, CY;
Goodall, RL;
Nunn, AJ;
Rusen, ID;
Meredith, SK;
(2022)
QT prolongation in the STREAM Stage 1 Trial.
The International Journal of Tuberculosis and Lung Disease
, 26
(4)
pp. 334-340.
10.5588/ijtld.21.0403.
Preview |
Text (Version of record)
QT prolongation in STREAM_IJTLD 2022.pdf - Published Version Download (406kB) | Preview |
Preview |
Text (Supplementary Material)
iutld_ijtld_21.0403_supplementarydata1.pdf - Published Version Download (661kB) | Preview |
Abstract
BACKGROUND: STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the contemporaneous WHO-recommended regimen. This regimen included moxifloxacin and clofazimine, known to cause QT prolongation, and severe prolongation was more common on the Short regimen. Here we investigate risk factors for QT prolongation with the Short regimen.METHODS: Data from patients prescribed the Short regimen (n = 282) were analysed to identify risk factors for severe QT prolongation (QT/QTcF ≥500 ms or ≥60 ms increase in QTcF from baseline).RESULTS: Of the 282 patients on the Short regimen, 94 (33.3%) developed severe QT prolongation: 31 QT/QTcF ≥500 ms; 92 experienced ≥60 ms QTcF increase from baseline. The median time to QT/QTcF ≥500 ms was 20 weeks (IQR 8-28), and the time to ≥60 ms increase from baseline was 18 weeks (IQR 8-28). Prolongation ≥500 ms was most frequent in patients from Mongolia (10/22, 45.5%) compared with 3.5-11.9% at other sites, P < 0.001. Higher baseline QTcF increased risk of prolongation to ≥500 ms (QTcF ≥400 ms: OR 5.99, 95% CI 2.04-17.62).CONCLUSION: One third of patients on the Short regimen developed severe QT prolongation. QT/QTcF ≥500 ms was more common in patients from Mongolia and in those with a higher baseline QTcF, which may have implications for implementation of treatment.
| Type: | Article |
|---|---|
| Title: | QT prolongation in the STREAM Stage 1 Trial |
| Location: | France |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.5588/ijtld.21.0403 |
| Publisher version: | https://doi.org/10.5588/ijtld.21.0403 |
| Language: | English |
| Additional information: | © The Authors 2022. This article is Open Access under the terms of the Creative Commons CC BY licence (https://creativecommons.org/licenses/by/4.0/). |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10146875 |
Archive Staff Only
 |
View Item |
